Quantifying antibody-mediated neutralization of SARS-CoV-2 directly in serum

Quantifying antibody-mediated neutralization of SARS-CoV-2 directly in serum
New Scientific Publication
The emergence of mutant variants of SARS-CoV-2 and associated concerns about the effects of these mutations on the efficacy of vaccines and therapeutics has underscored the vital importance of understanding the antibody response to SARS-CoV-2.

In our recent paper “In vitro measurements of protein–protein interactions show that antibody affinity governs the inhibition of SARS-CoV-2 spike/ACE2 binding in convalescent serum” we showcase the unique capabilities of our Fluidity One-W Serum platform and describe:

A new type of in-solution receptor-binding competition assay that quantifies the affinity, concentration, and neutralization potential of antibodies against the SARS-CoV-2 spike protein
The ability of this platform to accurately and quantitatively profile the underlying protein interactions directly in serum
If you have any questions about our technology or would like to see how the unique capabilities of the Fluidity One-W Serum can support your research, please get in touch and we will be happy to discuss your projects with you.